Major funding announced to develop materials and cell based treatment for diabetes
- 16 July 2015
A research consortium, in which the Oxford Consortium for Islet Transplantation is a member, has been awarded major new EU funding to develop novel treatment options for reversing diabetes.
The DRIVE (Diabetes Reversing Implants with enhanced Viability and long-term Efficacy) consortium involves fourteen partners from seven European countries and has received €8.9 million funding as part of the Horizon 2020 Research and Innovation Framework Programme.
The DRIVE programme will develop natural materials and new surgical devices to enhance the transplant and survival of insulin producing pancreatic islets for the treatment of diabetes.